Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 14/20 | 0.47 |
| ▸ | PDE4A | P27815 | 7/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19899988 | 0.87 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL20817334 | 0.87 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL3795836 | 0.87 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL3798842 | 0.86 | CASP6 (0.52) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL3492009 | 0.85 | PDE4D (0.50) | PDE4DPDE4APDE4BPDE4CKMT2A | |
| SCHEMBL3803162 | 0.82 | PDE4D (0.50) | PDE4DPDE4APDE4BPDE4CKAT2B | |
| SCHEMBL7355219 | 0.80 | PDE4D (0.49) | PDE4DPDE4APDE4BPDE4CKAT2B | |
| SCHEMBL29189681 | 0.79 | VCAM1 (0.48) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL19175683 | 0.78 | ALDH1A1 (0.54) | PDE5AKMT2AALDH1A1LMNAALOX12 | |
| SCHEMBL29189597 | 0.77 | CASP6 (0.56) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | disclosed |
| EP-1899353-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DeveloGen Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, PDXK | PDE4D 1587/4885PDE4A 1052/4885PDE4B 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.